Loading the company…
Loading the company…
㈜메디안스
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2012. Industry: Cosmetics (K-Beauty). Revenue for 2025 was ₩32.8bn. It has 35 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2014-10-28 · latest registration 2016-11-18 · newest first
본 발명은 신규 펩타이드 및 성장인자 콤플렉스(복합물)를 함유한 상처 재생 및 피부 진정용 화장료 조성물에 관한 것으로, 더욱 상세하게는 상처 재생 및 피부 진정에 효능을 지닌 신규 펩타이드(prospin), 그리고 상기 펩타이드와 여러 성장인자를 함유한 성장인자 콤플렉스가 함유된 상처 재생 및 피부 진정 효과를 지닌 화장료 조성물에 관한 것이다. 본 발명에 따른 펩타이드 그리고 EGF, bFGF, SCF, PGF를 더 함유하는 복합물은 피부 진정능, 피부 상처 재생능을 가지고 있어, 특히 피부 레이저 시술 후 도포를 통해 피부를 보호, 재생하는데 탁월한 효과를 가지고 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 28.0 | 32.8 |
| Cost of sales | 8.0 | 9.6 |
| Gross profit (loss) | 20.0 | 23.2 |
| Selling, general and administrative expenses | 10.3 | 18.0 |
| Operating income (loss) | 9.8 | 5.2 |
| Non-operating income | 0.8 | 0.4 |
| Other gains | 0.0 | 0.0 |
| Finance income | 0.3 | 0.3 |
| Other | 0.5 | 0.1 |
| Non-operating expenses | 1.8 | 0.2 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.1 | 0.1 |
| Other | 1.7 | 0.2 |
| Profit (loss) before tax | 8.8 | 5.4 |
| Income tax expense | 2.0 | 1.2 |
| Net income (loss) | 6.8 | 4.1 |
Revenue ₩32.8bn, up 17.1% YoY.
Operating margin 15.9% (prior 34.8%).
Net income ₩4.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06